Skip to content

Study · Animal study (in vivo) · mouse · 2024

6 results

The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.

Thomas L, Martel E, Rist W, Uphues I, Hamprecht D, Neubauer H, Augustin R

Diabetes, obesity & metabolism1 Apr 2024Cited by 10 (Europe PMC)

PMID38560764 (opens in a new tab)DOI10.1111/dom.15551 (opens in a new tab)PepBankPUB-38560764
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In lean mice, survodutide improved acute oral glucose tolerance (AUC of 54% versus vehicle).

    In plain wordsIn lean mice, survodutide improved the handling of a sugar load compared with vehicle (AUC of 54%).

    Peptide
    Survodutide
    Outcome
    DecreaseAcute oral glucose tolerance (AUC) versus vehicle
    Study

    mousen: not reported in source

    lean mice
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 nmol/kgAs given in this study (mouse).

    Measurements

    Glucose AUC
    54%
    survodutide vs vehicle

    Source sentences

    Summary
    Survodutide, BI 456908 and BI 456897 were selected for in-depth pharmacological profiling based on the significant improvement in acute oral glucose tolerance achieved (area under the curve [AUC] of 54%, 57% and 60% vs. vehicle
    2 context sentences
    Summary · context
    measuring improvement in oral glucose tolerance (30 nmol/kg)
    Summary · context
    Upon acute dosing in lean mice, target engagement biomarkers
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In lean mice, the improvement in acute oral glucose tolerance with survodutide was comparable to semaglutide.

    In plain wordsIn lean mice, survodutide improved glucose tolerance about as much as semaglutide did.

    Peptide
    Survodutide
    Outcome
    No significant changeAcute oral glucose tolerance (AUC) versus semaglutide
    Study

    mousen: not reported in source

    lean mice
    Comparator
    Semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 nmol/kgAs given in this study (mouse).

    Measurements

    Glucose AUC
    54%
    survodutide vs vehicle
    Glucose AUC
    45%
    semaglutide vs vehicle

    Source sentences

    Summary
    Survodutide, BI 456908 and BI 456897 were selected for in-depth pharmacological profiling based on the significant improvement in acute oral glucose tolerance achieved (area under the curve [AUC] of 54%, 57% and 60% vs. vehicle) that was comparable to semaglutide (AUC of 45% vs. vehicle
    1 context sentence
    Summary · context
    measuring improvement in oral glucose tolerance (30 nmol/kg)
  3. 03AnimalAnimal study (in vivo)Mechanism

    In lean mice, survodutide and two other dual agonists increased hepatic NNMT mRNA expression 15- to 17-fold versus vehicle, showing glucagon receptor engagement.

    In plain wordsIn lean mice, survodutide and two similar compounds raised a liver marker of glucagon receptor activity 15- to 17-fold versus vehicle.

    Peptide
    Survodutide
    Outcome
    IncreaseHepatic NNMT mRNA expression (GCGR engagement)
    Study

    mousen: not reported in source

    lean mice
    Comparator
    Vehicle
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    100 nmol/kgAs given in this study (mouse).

    Measurements

    Hepatic NNMT mRNA increase
    15 to 17 fold
    three dual agonists vs vehicle

    Source sentences

    Summary
    hepatic NNMT mRNA expression (increased by 15- to 17-fold vs. vehicle
    1 context sentence
    Summary · context
    increase in plasma fibroblast growth factor-21 (FGF21) and liver nicotinamide N-methyltransferase (NNMT) mRNA expression (100 nmol/kg)
  4. 04AnimalAnimal study (in vivo)Mechanism

    In lean mice, survodutide and two other dual agonists increased plasma FGF21 concentrations by up to sevenfold versus vehicle.

    In plain wordsIn lean mice, survodutide and two similar compounds raised blood FGF21, a glucagon receptor marker, by up to sevenfold versus vehicle.

    Peptide
    Survodutide
    Outcome
    IncreasePlasma FGF21 concentration (GCGR engagement)
    Study

    mousen: not reported in source

    lean mice
    Comparator
    Vehicle
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    100 nmol/kgAs given in this study (mouse).

    Measurements

    Plasma FGF21 increase
    ≤ 7 fold
    three dual agonists vs vehicle

    Source sentences

    Summary
    plasma FGF21 concentrations (increased by up to sevenfold vs. vehicle
    1 context sentence
    Summary · context
    increase in plasma fibroblast growth factor-21 (FGF21) and liver nicotinamide N-methyltransferase (NNMT) mRNA expression (100 nmol/kg)
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese mice, survodutide at 30 nmol/kg once daily lowered body weight by 25% from baseline.

    In plain wordsIn mice with diet-induced obesity, daily survodutide lowered body weight by 25% from the starting weight.

    Peptide
    Survodutide
    Outcome
    DecreaseBody weight lowering from baseline
    Study

    mousen: not reported in source

    diet-induced obese mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    30 nmol/kg once dailyAs given in this study (mouse).

    Measurements

    Body weight lowering
    25%
    survodutide 30 nmol/kg once daily

    Source sentences

    Summary
    In DIO mice, survodutide (30 nmol/kg/once daily), BI 456908 (30 nmol/kg/once daily) and BI 456897 (10 nmol/kg/once daily) achieved a body weight-lowering efficacy from baseline of 25%, 27% and 26%, respectively.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic db/db mice, survodutide at 10 and 20 nmol/kg once daily significantly lowered glycated haemoglobin by 0.4%-0.6%.

    In plain wordsIn diabetic mice, daily survodutide lowered glycated haemoglobin, a long-term blood sugar marker, by 0.4% to 0.6%.

    Peptide
    Survodutide
    Outcome
    DecreaseGlycated haemoglobin
    Study

    mousen: not reported in source

    diabetic db/db mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 and 20 nmol/kg once dailyAs given in this study (mouse).

    Measurements

    HbA1c reduction
    0.4 to 0.6%
    survodutide and BI 456908

    Source sentences

    Summary
    In db/db mice, survodutide and BI 456908 (10 and 20 nmol/kg/once daily) significantly lowered glycated haemoglobin (0.4%-0.6%); no significant effect was observed for BI 456897 (3 and 7 nmol/kg/once daily).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.